35 results
P
PCOS patients
I/C
Kuntai capsule combined with letrozole (LE), Letrozole (LE) alone
O
Efficacy in improving ovarian function and regulating sex hormone levels
P
female, smoker, manual laborer, hypercholesterolemic
I/C
O
LE
P
GEP-NENs
I/C
surgery, chemoembolisation, radiofrequency ablation, biological therapy, somatostatin analogs, PRRT therapy (177Lu-DOTATATE)
O
malignant progression, resistance to treatment, neoplastic process
P
GEP-NENs
I/C
neoadjuvant therapy, no neoadjuvant therapy
O
effectiveness and safety
P
patients with bone metastases (BMs) and neuroendocrine neoplasms (NENs)
I/C
management of BMs, patients without BMs
O
overall survival (OS)
P
patients with lateral epicondylitis (LE)
I/C
extracorporeal shock wave therapy (ESWT), other methods
O
pain and functional impairment (loss of grip strength)
P
patients with type 2 diabetes mellitus (T2DM)
I/C
aquatic exercise (AE), land-based exercise (LE), non-intervention control (Ctrl)
O
6‑min walking distance (6MWD), maximal oxygen uptake (VO2max), resting heart rate (RHR), resting systolic (RSBP) and diastolic blood pressures (RDBP)
P
women with diminished ovarian reserve (DOR)
I/C
progestin-primed ovarian stimulation (PPOS), clomiphene citrate (CC)/letrozole (LE) plus gonadotropin
O
clinical pregnancy rate
P
women with breast cancer in the Eastern Mediterranean Region (EMR)
I/C
none, survival rates of women with breast cancer in different age groups and countries in the EMR
O
pooled 1-, 3-, 5- and 10-year survival rates
P
menopausal women
I/C
Fezolinetant, placebo
O
decrease in vasomotor symptoms frequency and severity, safety outcomes